|  |  |  |
| --- | --- | --- |
| **AGENDA**  **POETIC Summer Meeting**  **July 27 and 28, 2017**    **The Solara**  **187 Kananaskis Way**  **Canmore, AlbertaPoeticLogo_Rework_Full.jpg**  **Canada** | | |
| **Time** | | **Session** |
| **Wednesday, July 26th** | | |
| **4:00 - 5:00 PM MT**  **(6:00 – 7:00 PM EST)** | | **Board of Directors Meeting**  **(Closed Meeting)** |
| **5:00 PM MT** | | **Dinner**  **Closed to Board of Directors** |
| **Thursday, July 27th** | | |
| ***All presentations include 15 min question and answer sessions and group discussions. This meeting is accredited by the Royal College of Physicians and Surgeons of Canada for Continuing Medical Education (CME).*** | | |
| **8:00 – 8:30 AM** | | **Registration/Breakfast** |
| **8:30 – 8:45 AM** | | **Greetings/Introductions**  *Victor Lewis, MD, Division Head, Hematology/Oncology and Bone Marrow Transplantation, Alberta Children’s Hospital*  **Welcome Address**  *Tanya Trippett, MD,* *Memorial Sloan Kettering Cancer Center.*  *Co-Founder and Director, POETIC* |
| **8:45 – 9:45 AM** | | **Keynote Address: Genomics Guided Therapeutics in Myeloma**  *Nizar Bahlis, MD, Associate Professor, Cumming School of Medicine,*  *University of Calgary* |
| **9:45 -10:00 AM** | | **Break** |
| **10:00 - 10:30 AM** | | **MERCK Pediatric pipeline presentation:** **PD-(L)1 pathway in pediatric cancers**  *Andre Galarneau, PhD, Director, Medical Affairs Oncology, Merck Canada Inc.* |
| **10:30 - 11:30 AM** | | **Genentech/Roche iMATRIX Update and Upcoming Molecules**  *Stephen Simko, MD, Associate Medical Director, iPODD* |
| **11:30 -12:00 PM** | | **Multi-Center Biobanking Study**  *Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center*  *Sri Ambati, MD, Memorial Sloan Kettering Cancer Center*  *Aru Narendran, MD, PhD, Alberta Children’s Hospital* |
| **Lunch *(Abstract Presentations)*** | | |
| **Afternoon Session** | | |
| **1:00 – 5:15 PM** | | **POETIC Translational Genomics Program**  *Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center*  *Aru Narendran, MD, PhD, Alberta Children’s Hospital* |
| **1:00 -1:30 PM** | | **Update from Center for Molecular Oncology**  *Dilmi Perera, PhD, Memorial Sloan Kettering Cancer Center* |
| **1:30 - 2:00 PM** | | **Update from POETIC Exosome Developmental Laboratory**  *David Lyden, MD, PhD, Weill Cornell Medical Center* |
| **2:00 - 2:30 PM** | | **Update from Robert Arceci Epigenomics Program**  *DNA Program*  *Bodour Salhia, PhD, University of Southern California* |
| **2:30 – 3:00 PM** | | **Update from Robert Arceci Epigenomics Program**  *RNA Program*  *Olga Kovalchuk, MD, PhD, University of Lethbridge* |
| **3:00-3:15 PM** | | **Break** |
| **3:15 – 3:45 PM** | | **Update from POETIC Proteomic Developmental Laboratory**  *Michael Roehrl, MD, PhD, Memorial Sloan Kettering Cancer Center* |
| **3:45 – 4:30 PM** | | **PDX/Organoid Model Systems**  *Rajasekhar Vinagolu, PhD, Memorial Sloan Kettering Cancer Center*  *Aru Narendran, MD, PhD, Alberta Children’s Hospital*  *Olga Kovalchuk, MD, PhD, University of Lethbridge* |
| **4:30 – 5:00 PM** | | **Immunologic Profiling in Pediatric Tumors**  *Srikanth Ambati, MD, Memorial Sloan Kettering Cancer Center* |
| **5:00 – 5:30 PM** | | **cBioPortal**  *Nikolaus Schultz, PhD, Memorial Sloan Kettering Cancer Center* |
| **5:15 PM** | | **Meeting Adjourn** |
| |  | | --- | | ***Dinner*** | | | |
| **Friday, July 28th** | | |
| **7:30 – 8:00 AM** | **Registration/Breakfast** | |
| **8:00 – 8:40 AM**  **8:40 – 9:00AM** | ***PI Meeting (Closed for 1st 40 minutes)***  *Tanya Trippett, MD, Co-Founder and Director POETIC*  *Cynthia Herzog, MD, MD Anderson Cancer Center*  *Lisa McGregor, MD, Pennsylvania State Medical Center*  *Joseph DeStefano, Memorial Sloan Kettering Cancer Center*  ***Town Hall (Last 20 minutes Open Session)*** | |
| **9:00 – 10:00 AM** | **Preclinical Development of PV-10**  *Eric Wachter, PhD, Chief Technology Officer and Director, Provectus Biopharmaceuticals, Inc.*  *Stephanie Hansen, Director of Clinical Operations*  **Clinical Development of PV-10**  *Presentation by Aru Narendran, MD, PhD/Olga Kovalchuk, MD, PhD*  *Presentation by Srikanth Ambati, MD*  *Presentation of Protocol Development by Tanya Trippett,MD* | |
| **10:00 – 10:15 AM** | **Break** | |
| **10:15 – 11:15 AM** | **Preclinical and Clinical Development of Taurolidine NanoPro™**  *Tony Pfaffle, MD, Chief Scientific Officer, Cormedix, Inc.*  *Steve Laumas, MD, Advisor, NanoProteagen*  *Presentation by Aru Narendran, MD, PhD*  *Presentation by Srikanth Ambati, MD* | |
| **11:15 – 12:00 PM** | **Preclinical Development of miR loaded Exosomal Vesicles**  *Stephen Gould, PhD, Professor Biologic Chemistry, Johns Hopkins University*  *Presentation by David Lyden, MD, PhD*  *Presentation by Aru Narendran, MD, PhD*  *Presentation by Olga Kovalchuk, MD, PhD* | |
| **Lunch *(Abstract Presentations)*** | | |
| **1:00 – 1:15 PM** | **Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide**  *Co-PI: Jessica Boklan, MD and Aru Narendran, MD, PhD* | |
| **1:15 – 1:30 PM** | **Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed Session)**  *Co-PI: Srikanth Ambati, MD and Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center*  *Joseph DeStefano, Memorial Sloan Kettering Cancer Center* | |
| **1:30 - 1:45 PM** | **LOI: Phase I/II trial using Selinexor with Fludarabine and Cytarabine**  *Norman Lacayo, MD, Lucile Packard Children’s Hospital*  *Jeffrey Rubinitz, MD, PhD, St. Jude Children’s Research Hospital*  *Karyopharm* | |
| **1:45 – 2:15 PM** | **Neuro-Oncology Section**  **Molecular Targeted Therapies for Pediatric Brain Tumors: Opportunities and Lessons Learned**  *Matthias Karajannis, MD,**Memorial Sloan Kettering Cancer Center* | |
| **2:15 - 2:45 PM** | **Preclinical Models for Brain Tumors**  *Michelle Monje, MD, PhD, Stanford University* | |
| **2:45 – 4:00 PM** | **Elephant P53 in nanoparticles as a therapeutic agent in Sarcomas**  *Joshua Schiffman, MD,* *Professor of Pediatrics, Adjunct Professor, Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, UT*  **The Notch—GFI1—LSD1 axis as a therapeutic target in T-ALL**  *Michael E. Engel, MD, PhD, Associate Professor of Pediatrics, Director Pediatric Hematology/Oncology Fellowship Program, Division of Pediatric Hematology/Oncology, Attending Physician Primary Children’s Hospital, Adjunct Associate Professor of Oncological Sciences, Co-Director MD/PhD Training Program, Investigator, Huntsman Cancer Institute, University of Utah School of Medicine* | |
| **4:00 PM** | **Adjourn** | |
|  | | |